Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.40 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.40 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.40 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.40 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.40 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.40 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82152 | 1.00 | MAPT (0.50) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Dacisteine SCHEMBL2402188 | 0.82 | MAPT (0.55) | MAPTKDM4ETHRBALOX15NFKB1 | |
| Dacisteine SCHEMBL1814125 | 0.82 | MAPT (0.55) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL5801290 | 0.82 | MAPT (0.35) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL5801287 | 0.82 | MAPT (0.35) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL25329304 | 0.78 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL4952983 | 0.78 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL308082 | 0.78 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL13921443 | 0.78 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL16745722 | 0.78 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120009437-A | Method for simultaneously measuring multiple volatile organic compounds metabolites in urine | 中国疾病预防控制中心环境与健康相关产品安全所 | 2025-05-16 | — | — | CN | claimed |
| WO-2025038540-A2 | BRAIN MODULATION SYSTEMS AND METHODS | SPIRE THERAPEUTIC, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| EP-4417061-A1 | FOOD SUPPLEMENT FOR ANIMALS, PREPARATION METHOD THEREOF AND USE OF SAME | Adibio, S.l. (ES) | 2024-08-21 | — | — | EP | claimed |
| CN-118067976-A | Application of metabolic markers in preparation of products for predicting or prognosis evaluation of diabetes curative effect | 首都医科大学附属北京友谊医院 | 2024-05-24 | — | — | CN | claimed |
| US-20240159775-A1 | WASTEWATER-BASED EPIDEMIOLOGY METHODS FOR ASSESSING POPULATION HEALTH | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2024-05-16 | — | — | US | claimed |
| EP-4313009-A1 | MAYTANSINE-ANTIBODY CONJUGATES AND METHODS OF USING SAME | Angiex, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| EP-4167858-A1 | VENTRAL STRIATUM ACTIVITY | Ichilov Tech Ltd. (IL) | 2023-04-26 | — | — | EP | claimed |
| WO-2023062251-A1 | FOOD SUPPLEMENT FOR ANIMALS, PREPARATION METHOD THEREOF AND USE OF SAME | ADIBIO, S.L. (ES) | 2023-04-20 | — | — | WO | claimed |
| WO-2022204568-A1 | MAYTANSINE-ANTIBODY CONJUGATES AND METHODS OF USING SAME | ANGIEX, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| EP-2976061-B1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | DENTALMED PHARM HOLDING LTD (BE) | 2019-10-16 | — | — | EP | claimed |
| EP-2976061-A1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | Dentalmed Pharm Holding Ltd. (BE) | 2016-01-27 | — | — | EP | claimed |
| WO-2014147613-A1 | COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS | DENTALMED PHARM HOLDING LTD. (BE) | 2014-09-25 | — | — | WO | claimed |
| JP-4531141-B2 | — | — | 2010-08-25 | — | — | JP | claimed |
| JP-2002511862-A | — | — | 2002-04-16 | — | — | JP | claimed |
| EP-1011567-A1 | DRUG DELIVERY DEVICES AND METHODS FOR TREATMENT OF VIRAL AND MICROBIAL INFECTIONS AND WASTING SYNDROMES | Cryopreservation Technologies CC (ZA) | 2000-06-28 | — | — | EP | claimed |
| EP-1011567-A4 | DRUG DELIVERY DEVICES AND METHODS FOR TREATMENT OF VIRAL AND MICROBIAL INFECTIONS AND WASTING SYNDROMES | CRYOPRESERVATION TECH CC (ZA) | 2000-06-28 | — | — | EP | claimed |
| WO-1998056325-A1 | DRUG DELIVERY DEVICES AND METHODS FOR TREATMENT OF VIRAL AND MICROBIAL INFECTIONS AND WASTING SYNDROMES | CRYOPRESERVATION TECHNOLOGIES CC (ZA) | 1998-12-17 | — | — | WO | claimed |
| US-20260108206-A1 | REAL-TIME TRACKING OF CEREBRAL HEMODYNAMIC RESPONSE (RTCHR) OF A SUBJECT BASED ON HEMODYNAMIC PARAMETERS | ROPAMedics LLC | 2026-04-23 | — | — | US | disclosed |
| WO-1997022248-A9 | COMPOSITION FOR ORGAN CRYOPRESERVATION AND TREATMENT OF VIRAL AND BACTERIAL INFECTIONS | — | 1997-10-02 | — | — | WO | disclosed |
| WO-1997022248-A1 | COMPOSITION FOR ORGAN CRYOPRESERVATION AND TREATMENT OF VIRAL AND BACTERIAL INFECTIONS | CRYOPRESERVATION TECHNOLOGIES CC (ZA) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108206-A1 | REAL-TIME TRACKING OF CEREBRAL HEMODYNAMIC RESPONSE (RTCHR) OF A SUBJECT BASED ON HEMODYNAMIC PARAMETERS | TRPC6, PTGIR, OXTR | MAPT 344/4885KDM4E 4242/4885THRB 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.